Comparison of the inhibition potential of parthenolide and micheliolide on various UDP-glucuronosyltransferase isoforms

References

• Cao YF, Du Z, Zhu ZT, et al. (2017). Inhibitory effects of fifteen phthalate esters in human cDNA-expressed UDP-glucuronosyltransferase supersomes. Chemosphere 185:983–90.
   PubMed Web of Science ®Google Scholar
• Chen DW, Du Z, Zhang CZ, et al. (2017). The inhibition of UDP-glucuronosyltransferases (UGTs) by tetraiodothyronine (T4) and triiodothyronine (T3). Xenobiotica 48:1–18.
   PubMed Web of Science ®Google Scholar
• Chen S, Yueh MF, Bigo C, et al. (2013). Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11). Proc Natl Acad Sci USA 110:19143–8.
   PubMed Web of Science ®Google Scholar
• Chouinard S, Barbier O, Bélanger A. (2007). UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells. J Biol Chem 282:33466–74.
   PubMed Web of Science ®Google Scholar
• Czyz M, Lesiak-Mieczkowska K, Koprowska K, et al. (2010). Cell context-dependent activities of parthenolide in primary and metastatic melanoma cells . Br J Pharmacol 160:1144–57.
   PubMed Web of Science ®Google Scholar
• Di PA, Bocci G, Polillo M, et al. (2011). Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity. Curr Drug Metab 12:932–43.
   PubMed Web of Science ®Google Scholar
• Dong RH, Fang ZZ, Zhu LL, et al. (2012). Investigation of UDP-glucuronosyltransferases (UGTs) inhibitory properties of carvacrol. Phytother Res 26:86–90.
   PubMed Web of Science ®Google Scholar
• Erichsen TJ, Aehlen A, Ehmer U, et al. (2010). Regulation of the human bile acid UDP-glucuronosyltransferase 1A3 by the farnesoid X receptor and bile acids. J Hepatol 52:570–8.
   PubMed Web of Science ®Google Scholar
• Fahrmayr C, König J, Auge D, et al. (2012). Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol 165:1836–47.
   PubMed Web of Science ®Google Scholar
• Fang ZZ, Zhang YY, Ge GB, et al. (2010). Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction. Br J Clin Pharmacol 69:193–9.
   PubMed Web of Science ®Google Scholar
• Fang ZZ, Zhang YY, Ge GB, et al. (2011). Identification of cytochrome P450 (CYP) isoforms involved in the metabolism of corynoline, and assessment of its herb-drug interactions. Phytother Res 25:256–63.
   PubMed Web of Science ®Google Scholar
• Guzman ML, Rossi RM, Karnischky L, et al. (2005). The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105:4163–9.
   PubMed Web of Science ®Google Scholar
• Holcomb BK, Yip-Schneider MT, Waters JA, et al. (2012). Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells. J Gastrointest Surg 16:1333–40.
   PubMed Web of Science ®Google Scholar
• Igarashi R, Inoue T, Fujiyama N, et al. (2018). Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma. Med Oncol 35:51.
   PubMed Web of Science ®Google Scholar
• Innocenti F, Iyer L, Ramírez J, et al. (2001). Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 29:686–92.
   PubMed Web of Science ®Google Scholar
• Ji Q, Ding YH, Sun Y, et al. (2016). Antineoplastic effects and mechanisms of micheliolide in acute myelogenous leukemia stem cells. Oncotarget 7:65012–23.
   PubMedGoogle Scholar
• Jia Y, Zhou L, Tian C, et al. (2015). Dynamin-related protein 1 is involved in micheliolide-induced breast cancer cell death. Onco Targets Ther 8:3371–81.
   PubMed Web of Science ®Google Scholar
• Kato Y, Ikushiro S, Emi Y, et al. (2008). Hepatic UDP-glucuronosyltransferases responsible for glucuronidation of thyroxine in humans. Drug Metab Dispos 36:51–5.
   PubMed Web of Science ®Google Scholar
• Kawasaki BT, Hurt EM, Kalathur M, et al. (2009). Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: an integrated molecular profiling approach. Prostate 69:827–37.
   PubMed Web of Science ®Google Scholar
• Kiang TK, Ensom MH, Chang TK. (2005). UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106:97–132.
   PubMed Web of Science ®Google Scholar
• Kim SL, Liu YC, Seo SY, et al. (2015). Parthenolide induces apoptosis in colitis-associated colon cancer, inhibiting NF-κB signaling. Oncol Lett 9:2135–42.
   PubMed Web of Science ®Google Scholar
• Kolev JN, O’Dwyer KM, Jordan CT, et al. (2014). Discovery of potent parthenolide-based antileukemic agents enabled bylate-stage P450-mediated C—H functionalization. ACS Chem Biol 9:164–73.
   PubMed Web of Science ®Google Scholar
• Li L, Hu H, Xu S, et al. (2012). Roles of UDP-glucuronosyltransferases in phytochemical metabolism of herbal medicines and the associated herb-drug interactions. Curr Drug Metab 13:615–23.
   PubMed Web of Science ®Google Scholar
• Liu X, Cao YF, Ran RX, et al. (2015). New insights into the risk of phthalates: inhibition of UDP-glucuronosyltransferases. Chemosphere 144:1966–72.
   PubMed Web of Science ®Google Scholar
• Ma HY, Sun DX, Cao YF, et al. (2014). Herb-drug interaction prediction based on the high specific inhibition of andrographolide derivatives towards UDP-glucuronosyltransferase (UGT) 2B7. Toxicol Appl Pharmacol 277:86–94.
   PubMed Web of Science ®Google Scholar
• Marsh S, Hoskins JM. (2010). Irinotecan pharmacogenomics. Pharmacogenomics 11:1003–10.
   PubMed Web of Science ®Google Scholar
• Mathema VB, Koh YS, Thakuri BC, et al. (2012). Parthenolide, a sesquiterpene lactone, expresses multiple anti-cancer and anti-inflammatory activities. Inflammation 35:560–5.
   PubMed Web of Science ®Google Scholar
• Mohamed ME, Frye RF. (2011). Effects of herbal supplements on drug glucuronidation. Review of clinical, animal, and in vitro studies. Planta Med 77:311–21.
   PubMed Web of Science ®Google Scholar
• Ran R, Zhang C, Li R, et al. (2016). Evaluation and comparison of the inhibition effect of astragaloside IV and aglycone cycloastragenol on various UDP-glucuronosyltransferase (UGT) isoforms. Molecules 21:1616.
   Web of Science ®Google Scholar
• Sabolovic N, Humbert AC, Radominska-Pandya A, et al. (2010). Resveratrol is efficiently glucuronidated by UDP-glucuronosyltransferases in the human gastrointestinal tract and in Caco-2 cells. Biopharm Drug Dispos 27:181–9.
   Google Scholar
• Sun D, Zhang CZ, Ran RX, et al. (2017). In vitro comparative study of the inhibitory effects of mangiferin and its aglycone norathyriol towards UDP-glucuronosyl transferase (UGT) isoforms. Molecules 22:1008.
   Web of Science ®Google Scholar
• Wen J, You KR, Lee SY, et al. (2002). Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J Biol Chem 277:38954–64.
   PubMed Web of Science ®Google Scholar
• Zhang D, Qiu L, Jin X, et al. (2009). Nuclear factor-kappaB inhibition by parthenolide potentiates the efficacy of Taxol in non-small cell lung cancer in vitro and in vivo. Mol Cancer Res 7:1139–49.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Cao YF, Ran RX, et al. (2016). Strong specific inhibition of UDP-glucuronosyltransferase 2B7 by Atractylenolide I and III. Phytother Res 30:25–30.
   PubMed Web of Science ®Google Scholar
• Zhang S, Ong CN, Shen HM. (2004). Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett 208:143–53.
   PubMed Web of Science ®Google Scholar
• Zhang S, Won YK, Ong CN, et al. (2005). Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Curr Med Chem Anticancer Agents 5:239–49.
   PubMedGoogle Scholar
• Zucker SD, Qin X, Rouster SD, et al. (2001). Mechanism of indinavir-induced hyperbilirubinemia. Gastroenterology 120:12671–6.
   Web of Science ®Google Scholar